LY 235959CAS# 137433-06-8 |
- T0901317
Catalog No.:BCC1178
CAS No.:293754-55-9
- GW3965
Catalog No.:BCC1612
CAS No.:405911-09-3
- GW3965 HCl
Catalog No.:BCC3790
CAS No.:405911-17-3
- Fexaramine
Catalog No.:BCC7412
CAS No.:574013-66-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 137433-06-8 | SDF | Download SDF |
| PubChem ID | 131938 | Appearance | Powder |
| Formula | C11H20NO5P | M.Wt | 277.26 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in water | ||
| Chemical Name | (3S,4aR,6S,8aR)-6-(phosphonomethyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid | ||
| SMILES | C1CC2CNC(CC2CC1CP(=O)(O)O)C(=O)O | ||
| Standard InChIKey | STIRHCNEGQQBOY-QEYWKRMJSA-N | ||
| Standard InChI | InChI=1S/C11H20NO5P/c13-11(14)10-4-9-3-7(6-18(15,16)17)1-2-8(9)5-12-10/h7-10,12H,1-6H2,(H,13,14)(H2,15,16,17)/t7-,8-,9+,10-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Competitive NMDA receptor antagonist. |
LY 235959 Dilution Calculator
LY 235959 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.6067 mL | 18.0336 mL | 36.0672 mL | 72.1345 mL | 90.1681 mL |
| 5 mM | 0.7213 mL | 3.6067 mL | 7.2134 mL | 14.4269 mL | 18.0336 mL |
| 10 mM | 0.3607 mL | 1.8034 mL | 3.6067 mL | 7.2134 mL | 9.0168 mL |
| 50 mM | 0.0721 mL | 0.3607 mL | 0.7213 mL | 1.4427 mL | 1.8034 mL |
| 100 mM | 0.0361 mL | 0.1803 mL | 0.3607 mL | 0.7213 mL | 0.9017 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 15,16-Epoxy-15-ethoxy-6beta,13-dihydroxylabd-8-en-7-one
Catalog No.:BCN7428
CAS No.:1374328-47-8
- Diacerein
Catalog No.:BCN2291
CAS No.:13739-02-1
- Spathulatol
Catalog No.:BCN6877
CAS No.:1373888-27-7
- PF-5274857
Catalog No.:BCC3838
CAS No.:1373615-35-0
- Nω-Propyl-L-arginine hydrochloride
Catalog No.:BCC6965
CAS No.:137361-05-8
- GSK J4 HCl
Catalog No.:BCC2230
CAS No.:1373423-53-0
- GSK J1
Catalog No.:BCC2231
CAS No.:1373422-53-7
- Boc-Val-OH
Catalog No.:BCC3465
CAS No.:13734-41-3
- Boc-Thr(tBu)-OH
Catalog No.:BCC3452
CAS No.:13734-40-2
- Boc-Ser(tBu)-OH
Catalog No.:BCC3444
CAS No.:13734-38-8
- Boc-Sar-OH
Catalog No.:BCC3337
CAS No.:13734-36-6
- Boc-Phe-OH
Catalog No.:BCC3432
CAS No.:13734-34-4
- TUG 891
Catalog No.:BCC6235
CAS No.:1374516-07-0
- BRD4770
Catalog No.:BCC5525
CAS No.:1374601-40-7
- LEE011 succinate
Catalog No.:BCC4102
CAS No.:1374639-75-4
- LEE011 succinate hydrate
Catalog No.:BCC4103
CAS No.:1374639-79-8
- CO-1686 (AVL-301)
Catalog No.:BCC1490
CAS No.:1374640-70-6
- Rhapontisterone
Catalog No.:BCC8245
CAS No.:137476-71-2
- GNE0877
Catalog No.:BCC5369
CAS No.:1374828-69-9
- Regiolone
Catalog No.:BCN7193
CAS No.:137494-04-3
- 1-Benzoylpiperazine
Catalog No.:BCC8456
CAS No.:13754-38-6
- Poricoic acid A(F)
Catalog No.:BCN3741
CAS No.:137551-38-3
- Poricoic acid B
Catalog No.:BCN8260
CAS No.:137551-39-4
- VT-464 racemate
Catalog No.:BCC5399
CAS No.:1375603-36-3
Enhancement of morphine actions in morphine-naive and morphine-tolerant mice by LY 235959, a competitive antagonist of the NMDA receptor.[Pubmed:9112078]
Gen Pharmacol. 1997 Jan;28(1):61-4.
1. The effects of LY 235959, a competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, on the analgesic and hypothermic actions of morphine, were determined in nontolerant and morphine-tolerant mice. 2. LY 235959 enhanced the analgesic and hypothermic action of morphine in nontolerant mice. 3. LY 235959 also enhanced the analgesic and hypothermic actions of morphine in morphine-tolerant mice. LY 235959, injected before saline injection, had no effect on the antinociception or the body temperature. 4. It is concluded that competitive antagonism of the NMDA receptor enhances the pharmacologic actions of morphine both in morphine-naive and morphine-tolerant mice and that these actions differ from the noncompetitive antagonism of the NMDA receptors.
An NMDA antagonist (LY 235959) attenuates abstinence-induced withdrawal of planarians following acute exposure to a cannabinoid agonist (WIN 55212-2).[Pubmed:17306870]
Pharmacol Biochem Behav. 2007 Mar;86(3):499-504.
The mechanisms that facilitate the development and expression of cannabinoid physical dependence in humans and other mammals are poorly understood. The present experiments used a planarian model to provide evidence that pharmacological antagonism of NMDA receptors significantly attenuates the development of cannabinoid physical dependence. Abstinence-induced withdrawal from the cannabinoid agonist WIN 55212-2 (10 microM) was manifested as a significant (P<0.05) decrease in the rate of planarian spontaneous locomotor velocity (pLMV) when WIN 55212-2 (10 microM)-exposed planarians were placed into drug-free water. No change in pLMV occurred when WIN 55212-2 (10 microM)-exposed planarians were placed into water containing WIN 55212-2 (10 microM). WIN 55212-2 (10 microM)-exposed planarians placed into water containing LY 235959 (1 or 10 microM) did not display withdrawal (no significant difference, P>0.05, in pLMV). In addition, withdrawal was not observed (no significant difference, P>0.05, in pLMV) in planarians that were co-exposed to a solution containing WIN 55212-2 (10 microM) and LY 235959 (10 microM). The present results reveal that NMDA receptor activation mediates the development of cannabinoid physical dependence and the expression of cannabinoid withdrawal in planarians.
Competitive NMDA-receptor antagonists, LY 235959 and LY 233053, enhance the protective efficacy of various antiepileptic drugs against maximal electroshock-induced seizures in mice.[Pubmed:8681893]
Epilepsia. 1996 Jul;37(7):618-24.
PURPOSE: The objective of this study was to evaluate an interaction of two competitive N-methyl-D-aspartate (NMDA)-receptor antagonists, LY 235959 l(-)-3R,4aS,6R,8aR-6-(phosphonomethyl)-decahydroiso-qu inoline-3-carboxylic acid; < or = 0.5 mg/kg] or LY 233053 cis-(+/-)-4-[(2H-tetrazol-5-yl) methyl]piperidine-2-carboxylic acid; < or = 5 mg/kg] with carbamazepine, diphenylhydantoin, phenobarbital, or valproate magnesium against maximal electroshock-induced convulsions in mice. METHODS: Electroconvulsions were produced by means of an alternating current (ear-clip electrodes, 0.2-s stimulus duration, tonic hindlimb extension taken as the end point) delivered by a Hugo-Sachs stimulator (Type 221, reiburg, FRG). Adverse effects were evaluated in the chimney test (motor performance) and passive-avoidance ask (long-term memory). Plasma levels of antiepileptic rugs were measured by immunofluorescence. RESULTS: Both LY 235959 and LY 233053 ( < or = 0.5 and 5 mg/kg, respectively) did not influence the electroconvulsive threshold but potentiated the anticonvulsant action of all antiepileptics studied. The combined treatment of LY 233053 (5 mg/kg) with carbamazepine, diphenylhydantoin, or phenobarbital (providing a 50% protection against maximal electroshock) resulted in the impairment of long-term memory. No adverse effects were observed with combinations of LY 235959 with these antiepileptics. The combined treatment of valproate with either LY 235959 or LY 233053 was superior to valproate alone, as regards motor impairment, but not the impairment of long-term memory. Neither NMDA-receptor antagonist elevated the total plasma levels of antiepileptic drugs studied. CONCLUSIONS: It may be concluded that NMDA-receptor blockade leads to the enhanced anticonvulsive action of conventional antiepileptics against maximal electroshock-induced seizures. A pharmacokinetic interaction does not seem probable.
Anticonvulsant and adverse effects of MK-801, LY 235959, and GYKI 52466 in combination with Ca2+ channel inhibitors in mice.[Pubmed:9130287]
Pharmacol Biochem Behav. 1997 Apr;56(4):629-35.
This study was designed to investigate the influence of the calcium (Ca2+) channel inhibitors nicardipine, nifedipine, and flunarizine on the protective action of MK-801, LY 235959 [N-methyl-D-aspartate (NMDA) receptor antagonists], and GYKI 52466 (a non-NMDA receptor antagonist) against electroconvulsions in mice. Unlike nicardipine (15 mg/kg) or flunarizine (10 mg/kg) nifedipine (7.5 and 15 mg/kg) potentiated the protective potency of MK-801 (0.05 mg/kg), as reflected by significant elevation of the convulsive threshold (a CS50 value of the current strength in mA producing tonic hind limb extension in 50% of the animals). The protective activity of LY 235959 and GYKI 52466 was reflected by their ED50 values in mg/kg, at which the drugs were expected to protect 50% of mice against maximal electroshock-induced tonic extension of the hind limbs. Nicardipine (3.75 15 mg/kg), nifedipine (0.94-15 mg/kg), and flunarizine (2.5-10 mg/kg) in a dose-dependent manner markedly potentiated the antiseizure efficacy of LY 235959. Flunarizine (5 and 10 mg/kg) was the only Ca2+ channel inhibitor to enhance the protective action of GYKI 52466 against electroconvulsions. Except with MK-801 + flunarizine (motor performance) or GYKI 52466 + flunarizine (long-term memory), combination of NMDA or non-NMDA receptor antagonists with Ca2+ channel inhibitors produced an impairment of motor performance (evaluated in the chimney test) and long-term memory acquisition (measured in the passive avoidance task) as compared with vehicle treatment.
Competitive and non-competitive NMDA antagonists induce similar limbic degeneration.[Pubmed:7696633]
Neuroreport. 1994 Dec 20;5(18):2688-92.
Neural degeneration was observed in a similar set of limbic structures following the continuous administration of several NMDA antagonists (phencyclidine, dizocilpine, and LY235959). The earliest signs involved terminals and processes, followed by cell bodies. In retrosplenial cortex the predominant staining showed a distribution very similar to that observed for cholinergic innervations. Considerable degeneration was also observed in entorhinal cortex and its principal output, dentate gyrus of hippocampus, and in olfactory regions such as olfactory tubercle and tenia tecta, and in piriform cortex. These results, when considered together with those from studies of glucose metabolism following NMDA antagonists, suggest that a hypermetabolic circuit was involved, and indicate that both competitive and non-competitive NMDA antagonists can induce these effects.
